China Traditional Chinese Medicine : INSIDE INFORMATION - ISSUANCE OF THE SUPER & SHORT TERM COMMERCIAL PAPER AT THE NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED

中國中藥 控股 有 限公 司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 570)

INSIDE INFORMATION

ISSUANCE OF THE SUPER & SHORT TERM COMMERCIAL PAPER

AT THE NATIONAL ASSOCIATION OF FINANCIAL MARKET

INSTITUTIONAL INVESTORS

This announcement is made by China Traditional Chinese Medicine Holdings Co. Limited (the "Company", together with its subsidiaries, the "Group") pursuant to Rule 13.09(2) of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 17 September 2019, the Company received a notice (the "Notice") issued by the National Association of Financial Market Institutional Investors (the "Association") which stated that, among other things, (i) the issuance (the "Issue") of a Super & Short-term Commercial Paper (the "Note") with an aggregated amount of RMB2.8 billion is duly registered at the Association; (ii) the Notes may be issued by the Company in multiple tranches within two years from the date of the Notice; and (iii) the Company shall comply with the applicable rules, regulations and requirements stipulated by the Association in respect of the Issue, including the disclosure requirements and the intended use of the proceeds from the Issue.

The board of directors of the Company is pleased to announce that on 14 October 2019, the Company has completed the issuance of the Note, for an aggregate amount of RMB2.8 billion, with a maturity of two hundred and seventy days and coupon rate of 3.19% per annum. The proceeds from the Issue is intended to be used for the repayment of RMB2.5 billion Mid-term notes and its interest expenses which will be matured in November 2019, and used as the working capital of the subsidiaries of the Group.

1

A memorandum containing information of the Issue has been disclosed on the website of China Money (http://www.chinamoney.com.cn/) and Shanghai Clearing House (http://www. shclearing.com/).

By Order of the Board

China Traditional Chinese Medicine Holdings Co. Limited

WU Xian

Chairman

Hong Kong, 14 October 2019

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. WU Xian, Mr. WANG Xiaochun and Mr. YANG Wenming are executive Directors; Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.

2